Multiple outlets discuss a potential “next generation” of GLP-1-based obesity medicines and what could come to the UK. The reporting describes how, since the start of the decade, GLP-1 treatments have become major blockbuster options for weight loss, with Britain’s use focused largely on injectable formulations. The coverage suggests that future options may include different dosing formats, such as tablet therapies, and references “new” obesity injection treatments that could become available. One article frames the possible new products as potentially more affordable than existing GLP-1 medicines, specifically comparing with Mounjaro. However, the sources provided do not give detailed information on which specific drugs are approved in the UK, the exact pricing, or the timelines for introduction, and they do not cite regulatory decisions or prescribing guidelines. Overall, the materials point to an evolving GLP-1 market in which UK access could extend beyond current injections, potentially offering alternatives in administration and cost, pending availability and approval.